Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 600MPE | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 7791.018 | 0.7952 | 0.5302 | 0.8558 | ||
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7448.084 | 0.9439 | 0.9595 | 2.8225 | |
| MCF7 | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 7874.018 | 0.5901 | 0.4529 | 1.6506 | ||
| SUM225CWN | HER2amp | Basal A | 5-DFUR | TYMS | TYMS | 8 | uM | 12098.143 | 0.9805 | 0.9602 | 0.9820 | |
| HCC38 | TNBC | Basal B | CGC-11047 | Polyamine analogue | 8 | uM | 9469.026 | 0.8118 | 0.6833 | 1.2092 | ||
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7469.084 | 0.9028 | 0.9022 | 2.0377 | |
| Hs 578T | TNBC | Basal B | CGC-11047 | Polyamine analogue | 8 | uM | 9511.034 | 0.6538 | 0.3673 | 1.1177 | ||
| SUM52PE | HR+ | Luminal | 5-DFUR | TYMS | TYMS | 8 | uM | 11852.143 | 1.0920 | 1.1485 | 1.2284 | |
| MDA-MB-468 | TNBC | Basal A | CGC-11047 | Polyamine analogue | 8 | uM | 7907.018 | 0.5115 | 0.2873 | 1.5217 | ||
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5902.084 | 0.9841 | 0.9764 | 1.3532 | |
| MDA-MB-415 | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 7897.018 | 0.8329 | 0.6108 | 0.8448 | ||
| UACC-812 | HER2amp | Luminal | 5-DFUR | TYMS | TYMS | 8 | uM | 10754.143 | 0.9271 | 0.8785 | 1.2072 | |
| 184A1 | NM | Basal | CGC-11047 | Polyamine analogue | 8 | uM | 10002.034 | 0.8249 | 0.5028 | 0.6736 | ||
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7449.084 | 0.9454 | 0.9483 | 2.1410 | |
| SUM52PE | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 9878.006 | 0.6987 | 0.5472 | 1.3968 | ||
| MCF12A | NM | Basal B | 5-DFUR | TYMS | TYMS | 8 | uM | 12365.143 | 0.6038 | 0.6189 | 2.3865 | |
| MDA-MB-468 | TNBC | Basal A | CGC-11047 | Polyamine analogue | 8 | uM | 7906.018 | 0.5007 | -0.0659 | 0.9087 | ||
| 184A1 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5894.084 | 0.4091 | 0.1401 | 1.5903 | |
| HCC1954 | HER2amp | Basal A | CGC-11047 | Polyamine analogue | 8 | uM | 7836.018 | 0.3550 | -0.2321 | 1.0819 | ||
| MDA-MB-415 | HR+ | Luminal | 5-DFUR | TYMS | TYMS | 8 | uM | 10938.143 | 0.7676 | 0.5420 | 1.0173 | |
| 600MPE | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 9120.034 | 0.8734 | 0.5949 | 0.5982 | ||
| HCC1937 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7453.084 | 0.9857 | 0.9817 | 1.5592 | |
| HCC1143 | TNBC | Basal A | CGC-11047 | Polyamine analogue | 8 | uM | 7810.006 | 0.8389 | 0.6696 | 0.9730 | ||
| SUM229PE | TNBC | - | 5-DFUR | TYMS | TYMS | 8 | uM | 11058.143 | 0.7629 | 0.7813 | 2.3374 | |
| LY2 | HR+ | Luminal | CGC-11047 | Polyamine analogue | 8 | uM | 7865.018 | 0.3858 | -0.1005 | 1.1920 |